Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C brings in €20.3mm in equity, €5mm in debt for Promethera; adds €10mm

Executive Summary

Promethera Biosciences SA NV, developer of the Promethera HepaStem cell therapy for treating inborn errors of metabolism and acquired liver diseases, raised €20.3mm ($25.2mm) in its Series C financing led by Vesalius Biocapital and Boehringer Ingelheim Venture Fund, which were joined by other returning backers Société Régionale d'Investissement de Wallonie, Shire, Mitsui Global Investment, Vives-Louvain Technology Transfer Office Fund, and business angels, and new investors SFPI-FPIM and SMS Investments. In addition, Promethera received €5mm in debt funding from the Walloon Region. The financing will support ongoing clinical development of Promethera HepaStem, which recently completed Phase I/II.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies